Ligne de temps
Gabriel Aymé
Ingénieur(e) de Recherche
18 mars 2024
publication
Cryo-EM structures of type IV pili complexed with nanobodies reveal immune escape mechanisms
Lire plus25 sept. 2023
publication
An original potentiating mechanism revealed by the cryo-EM structures of the human α7 nicotinic receptor in complex with nanobodies.
Lire plus22 juin 2023
25 mai 2023
publication
Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor.
Lire plus09 mars 2023
publication
Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases.
Lire plus25 oct. 2022
project
Advances in cancer immunotherapy development: VHH-based immune checkpoint inhibitors targeting the receptor ILT4
Lire plus01 janv. 2022
publication
Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein.
Lire plus10 avr. 2020
07 avr. 2020
publication
Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Lire plus16 janv. 2020
project
VenoMATIcs: Toward a Global Management of Venoms and Envenomations: the Pasteur network Translational Approach
Lire plus13 sept. 2018
publication
A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.
Lire plus01 avr. 2018
publication
Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor.
Lire plus27 févr. 2018
project
Toxins and nanobodies as subtype-specific ligands and allosteric modulators of nicotinic acetylcholine receptors (PTR Nicobinder)
Lire plus01 sept. 2017
publication
A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report.
Lire plus27 avr. 2017
publication
Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions.
Lire plus06 oct. 2016
publication
LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.
Lire plus17 févr. 2015